Immunic (NASDAQ:IMUX) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Immunic (NASDAQ:IMUX) in a research note issued to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $10.00 price target on the stock. HC Wainwright also issued estimates for Immunic’s Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($0.95) EPS, FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.60) EPS and FY2028 earnings at ($0.23) EPS.

IMUX has been the subject of several other research reports. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. B. Riley started coverage on shares of Immunic in a research note on Tuesday, August 27th. They issued a “buy” rating and a $6.00 target price for the company. Leerink Partners reiterated an “outperform” rating and issued a $5.00 target price on shares of Immunic in a report on Monday, September 9th. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Immunic has a consensus rating of “Buy” and a consensus price target of $11.80.

Immunic Stock Performance

Shares of IMUX opened at $1.20 on Monday. The firm has a market capitalization of $108.09 million, a P/E ratio of -0.98 and a beta of 1.88. Immunic has a 52 week low of $0.97 and a 52 week high of $2.11. The stock has a 50 day moving average price of $1.37 and a two-hundred day moving average price of $1.34.

Insider Buying and Selling at Immunic

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of the stock in a transaction dated Tuesday, November 12th. The shares were bought at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares in the company, valued at approximately $100,395. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Immunic

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Immunic in the first quarter valued at approximately $9,266,000. Ikarian Capital LLC grew its stake in Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after acquiring an additional 1,162,378 shares in the last quarter. Virtu Financial LLC bought a new stake in Immunic during the 1st quarter worth approximately $25,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after purchasing an additional 42,383 shares during the period. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.